Fergus Keane

484 total citations
40 papers, 271 citations indexed

About

Fergus Keane is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Fergus Keane has authored 40 papers receiving a total of 271 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 15 papers in Cancer Research and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Fergus Keane's work include Pancreatic and Hepatic Oncology Research (14 papers), Cancer Genomics and Diagnostics (13 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Fergus Keane is often cited by papers focused on Pancreatic and Hepatic Oncology Research (14 papers), Cancer Genomics and Diagnostics (13 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Fergus Keane collaborates with scholars based in United States, Ireland and United Kingdom. Fergus Keane's co-authors include Eileen M. O’Reilly, Malcolm MacConmara, Yvonne Connolly, Wungki Park, Michael Jeffers, T. P. Corrigan, Leslie Daly, Pádraig Daly, A.R. Tanner and G Lynch and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Clinical Cancer Research.

In The Last Decade

Fergus Keane

35 papers receiving 263 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fergus Keane United States 10 113 85 61 33 33 40 271
Neha Zutshi United States 9 112 1.0× 214 2.5× 35 0.6× 19 0.6× 20 0.6× 12 358
Miaorong She China 10 118 1.0× 254 3.0× 48 0.8× 15 0.5× 33 1.0× 15 389
Marília I. Figueira Portugal 12 50 0.4× 158 1.9× 67 1.1× 23 0.7× 30 0.9× 19 305
Yen‐Ying Chen Taiwan 9 63 0.6× 177 2.1× 45 0.7× 53 1.6× 10 0.3× 11 317
Jan Roger Olsen Norway 7 96 0.8× 192 2.3× 74 1.2× 14 0.4× 19 0.6× 9 293
Kelli Gaskins United States 8 106 0.9× 206 2.4× 100 1.6× 56 1.7× 15 0.5× 9 340
Lin‐wen Wu China 12 88 0.8× 225 2.6× 82 1.3× 12 0.4× 43 1.3× 18 381
Mee-Hyun Lee South Korea 3 127 1.1× 220 2.6× 102 1.7× 30 0.9× 19 0.6× 5 369
Suryanaryana V.S. Deo India 8 140 1.2× 264 3.1× 117 1.9× 38 1.2× 24 0.7× 8 454
Marina Riggio Argentina 8 97 0.9× 206 2.4× 63 1.0× 13 0.4× 60 1.8× 8 309

Countries citing papers authored by Fergus Keane

Since Specialization
Citations

This map shows the geographic impact of Fergus Keane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fergus Keane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fergus Keane more than expected).

Fields of papers citing papers by Fergus Keane

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fergus Keane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fergus Keane. The network helps show where Fergus Keane may publish in the future.

Co-authorship network of co-authors of Fergus Keane

This figure shows the co-authorship network connecting the top 25 collaborators of Fergus Keane. A scholar is included among the top collaborators of Fergus Keane based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fergus Keane. Fergus Keane is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Artz, Oliver, Peter Ntiamoah, Caroline Weipert, et al.. (2025). Acquired High Tumor Mutational Burden and Activity of Immunotherapy after Targeted Therapy in Microsatellite Stable Colorectal Cancer. Clinical Cancer Research. 32(6). 1100–1109. 1 indexed citations
2.
Keane, Fergus, Richard Tuli, Catherine O’Connor, et al.. (2024). Durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer (PDAC): Long-term outcomes and correlative insights.. Journal of Clinical Oncology. 42(16_suppl). 4174–4174.
3.
Chou, Joanne F., Marinela Capanu, Jennifer Park, et al.. (2024). Morbidity and mortality in patients with stage IV pancreatic adenocarcinoma and acute cholangitis: Outcomes and risk prognostication. Pancreatology. 24(4). 608–615. 2 indexed citations
4.
Keane, Fergus, Joanne F. Chou, Henry Walch, et al.. (2024). Precision medicine for pancreatic cancer: characterizing the clinicogenomic landscape and outcomes of KRAS G12C-mutated disease. JNCI Journal of the National Cancer Institute. 116(9). 1429–1438. 2 indexed citations
5.
Keane, Fergus, Henry Walch, Joanne F. Chou, et al.. (2024). Molecular and Clinical Determinants of Acquired Resistance and Treatment Duration for Targeted Therapies in Colorectal Cancer. Clinical Cancer Research. 30(12). 2672–2683. 5 indexed citations
6.
Keane, Fergus, Denis Evoy, James Geraghty, et al.. (2024). Real-World Analysis of the Clinical and Economic Impact of the 21-Gene Recurrence Score (RS) in Invasive Lobular Early-Stage Breast Carcinoma in Ireland. Current Oncology. 31(3). 1302–1310. 1 indexed citations
7.
O’Connor, Catherine, Henry Walch, Andrea Gazzo, et al.. (2024). Somatic mismatch repair deficiency in pancreas cancer (PC): Immune checkpoint blockade (ICB) outcomes and exploratory genomic analyses.. Journal of Clinical Oncology. 42(16_suppl). 4144–4144. 3 indexed citations
8.
Keane, Fergus, Catherine O’Connor, Wungki Park, Thomas Seufferlein, & Eileen M. O’Reilly. (2023). Pancreatic Cancer: BRCA Targeted Therapy and Beyond. Cancers. 15(11). 2955–2955. 14 indexed citations
9.
Capanu, Marinela, Fergus Keane, Danny N. Khalil, et al.. (2023). P-266 Outcomes in advanced hepatocellular carcinoma (HCC) patients (pts) treated with immune checkpoint inhibitors (ICI). Annals of Oncology. 34. S109–S109. 1 indexed citations
10.
11.
Keane, Fergus, Fiyinfolu Balogun, Catherine O’Connor, et al.. (2023). Adjuvant modified FOLFIRINOX (mFFX) for resected pancreatic cancer (PDAC): Real world outcomes (RWO).. Journal of Clinical Oncology. 41(4_suppl). 685–685. 1 indexed citations
12.
Tuli, Richard, Fergus Keane, Joshua D. Schoenfeld, et al.. (2023). A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer.. Journal of Clinical Oncology. 41(16_suppl). 4164–4164. 1 indexed citations
13.
Keane, Fergus, Joshua D. Schoenfeld, Catherine O’Connor, et al.. (2023). A phase II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced pancreatic adenocarcinoma (LA PDAC).. Journal of Clinical Oncology. 41(4_suppl). 725–725. 1 indexed citations
14.
Keane, Fergus, Wungki Park, Imane H. El Dika, et al.. (2023). Clinical outcomes for IDH1 mutant biliary tract cancer (BTC) treated with contemporary systemic therapy.. Journal of Clinical Oncology. 41(4_suppl). 513–513.
15.
Park, Wungki, Catherine O’Connor, Chaitanya Bandlamudi, et al.. (2022). Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice. Clinical Cancer Research. 28(21). 4782–4792. 13 indexed citations
16.
Keane, Fergus, Niamh M. Keegan, Philip J. O’Halloran, et al.. (2019). Similar overall survival with reduced vs. standard dose bevacizumab monotherapy in progressive glioblastoma. Cancer Medicine. 9(2). 469–475. 17 indexed citations
17.
Glynn, Nigel, et al.. (2012). Hypoglycaemia--more than skin deep. QJM. 106(4). 365–366.
18.
Whittock, Neil V., Huiying Wan, Frances J.D. Smith, et al.. (2001). Frameshift mutation in the V2 domain of keratin I causes the striate form of palmoplantar keratoderma. Journal of Investigative Dermatology. 117(3). 766–766. 2 indexed citations
19.
Keane, Fergus, et al.. (1997). Neonatal presentation of Caroli’s disease: Figure 1. Archives of Disease in Childhood Fetal & Neonatal. 77(2). F145–F146. 16 indexed citations
20.
Kerin, Michael J., Peter Gillen, J. R. T. Monson, et al.. (1995). Results of a prospective randomized trial using DTIC and interferon as adjuvant therapy for stage I malignant melanoma. European Journal of Surgical Oncology. 21(5). 548–550. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Neha Zutshi Breakdown of academic impact, for papers by Miaorong She Breakdown of academic impact, for papers by Marília I. Figueira Breakdown of academic impact, for papers by Yen‐Ying Chen Breakdown of academic impact, for papers by Jan Roger Olsen Breakdown of academic impact, for papers by Kelli Gaskins Breakdown of academic impact, for papers by Lin‐wen Wu Breakdown of academic impact, for papers by Mee-Hyun Lee Breakdown of academic impact, for papers by Suryanaryana V.S. Deo Breakdown of academic impact, for papers by Marina Riggio
Rankless by CCL
2026